Table 1. Patient and HCT Characteristics.
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| TBC (n = 263) | TT-BCNU (n = 275) | BEAM (n = 65) | ||
| Age, y | ||||
| Median (range) | 59 (23-76) | 60 (20-78) | 62 (23-74) | .16 |
| 50-59 | 93 (35) | 74 (27) | 22 (34) | |
| 60-69 | 104 (40) | 115 (42) | 28 (43) | |
| ≥70 | 12 (4) | 29 (10) | 6 (9) | |
| Female sex | 129 (49) | 125 (46) | 31 (48) | .70 |
| Race | ||||
| White | 219 (84) | 231 (84) | 54 (83) | .10 |
| African American | 4 (1) | 12 (4) | 3 (5) | |
| Asian | 25 (9) | 15 (6) | 4 (6) | |
| Othera | 2 (1) | 5 (2) | 3 (5) | |
| Missing | 13 (5) | 12 (4) | 1 (1) | |
| KPS | ||||
| 90-100 | 147 (56) | 121 (44) | 27 (42) | .02 |
| <90 | 111 (42) | 148 (53) | 38 (58) | |
| Missing | 7 (3) | 9 (3) | 0 | |
| HCT-CI | ||||
| 0 | 76 (29) | 59 (21) | 18 (28) | .26 |
| 1-2 | 79 (30) | 91 (33) | 16 (25) | |
| ≥3 | 108 (41) | 125 (46) | 31 (48) | |
| Remission status at HCT | ||||
| CR1 | 143 (54) | 166 (60) | 32 (49) | .18 |
| CR2+ | 58 (22) | 41 (15) | 15 (23) | |
| Any PR | 62 (24) | 68 (25) | 18 (28) | |
| Time from diagnosis to HCT, mo | ||||
| Median (range) | 8 (2-192) | 7 (3-139) | 11 (3-122) | <.001 |
| <6 | 84 (32) | 106 (39) | 14 (22) | .03 |
| ≥6 | 175 (67) | 169 (61) | 51 (78) | |
| Missing | 4 (1) | 0 | 0 | |
| Remission status and time from diagnosis to HCT | ||||
| CR1 and ≤6 mo | 69 (26) | 83 (30) | 9 (14) | .09 |
| CR1 and ≥6 mo | 71 (27) | 83 (30) | 23 (35) | |
| CR2+ and >6 mo | 58 (22) | 41 (15) | 15 (23) | |
| PR and ≤6 mo | 16 (6) | 23 (8) | 5 (8) | |
| PR and ≥6 mo | 46 (17) | 45 (17) | 13 (20) | |
| Missing | 3 (1) | 0 | 0 | |
| Rituximab used in conditioning | ||||
| Yes | 32 (12) | 21 (8) | 14 (22) | .004 |
| No | 231 (88) | 254 (92) | 51 (78) | |
| Year of HCT | ||||
| 2010-2014 | 93 (35) | 62 (23) | 35 (54) | <.001 |
| 2015-2018 | 170 (65) | 213 (77) | 30 (46) | |
| Follow-up of survivors, median (range), mo | 36 (1-120) | 24 (5-98) | 48 (6-97) | |
Abbreviations: BEAM, carmustine, etoposide, cytarabine, melphalan; CR1, first complete remission; CR2+, second or later complete remission; HCT, hematopoietic cell transplant; HCT-CI, hematopoietic cell transplant–comorbidity index; KPS, Karnofsky performance status; PR, partial remission; TBC, thiotepa, busulfan, cyclophosphamide; TT-BCNU, thiotepa, carmustine.
a
Other includes other race, for TBC (n = 2): Native Hawaiian/Pacific Islander (n = 1); American Indian/Alaska Native (n = 1); for TT-BCNU (n = 5): Native Hawaiian/Pacific Islander (n = 2); more than one race (n = 3); and for BEAM (n = 3): American Indian/Alaska Native (n = 1); more than one race (n = 2).